TBPH
ZYME
Cashing out, with a bonus IOU
Theravance Biopharma just agreed to be acquired by Zymeworks for $17.00 per share in cash, valuing the company at about $929 million. If you’re holding the stock, this is the kind of headline that turns a biotech into a deal ticket overnight.
The CVR twist
On top of the cash, shareholders get a contingent value right, or CVR. Translation: if Theravance’s ampreloxetine gets licensed, sold, or otherwise monetized within the next 10 years, shareholders get 80% of the net proceeds. So it’s not just a clean checkout at the register — there’s a little “maybe more later” coupon stapled to the deal.
What happens next?
The deal comes after a strategic review and still needs shareholder approval and the usual closing hoops. The companies expect it to close in the second half of 2026, which means the next stretch is all about paperwork, votes, and whether anything weird pops up to slow the parade.
Big picture
For Theravance investors, this shifts the story from pipeline speculation to merger math. And for Zymeworks, it’s a bigger swing at growth than a lab bench headline. Big picture: the market now has a price tag, a timeline, and a new reason to refresh the merger arb spreadsheets.